Our clinical experiences in patients with de novo and secondary metastatic breast cancers

Basit Öğe Kaydı
dc.contributor.authorTasci, Halil Ibrahim
dc.contributor.authorAlkan, Selman
dc.contributor.authorVarman, Alper
dc.date.accessioned2024-02-23T14:40:44Z
dc.date.available2024-02-23T14:40:44Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractAim: While breast cancer may be de novo, that is, metastatic at the time of diagnosis, a local tumor at initial diagnosis may metastasize to other regions over the course of treatment and follow-up. This study aimed to reveal the clinical, pathological, and survival differences in patients with de novo metastatic and secondary metastatic breast cancer who were followed up and treated in our clinic, and to investigate factors that may have an effect on survival.Material and Methods: The data of female patients who were diagnosed with metastatic breast cancer, treated, and followed up in our clinic between January 2000 and May 2021 were retrospectively analyzed. Patients were divided into two groups: the de novo metastatic disease group (Group 1) and the secondary metastatic disease group (Group 2). Clinical and pathological data of the groups were analyzed.Results: Patients with de novo metastatic disease most commonly had bone metastases. But in the secondary metastatic disease group, the most common metastasis type was multiorgan metastases. The rate of triple negativity was significantly lower in Group 1. When the groups were analyzed in terms of survival, the median time was 77 +/- 10.89 months in the de novo metastatic group and 66 +/- 10.15 months in the secondary metastatic group (p=0.05).Discussion: Our study demonstrated that de novo metastatic breast cancers had a better prognosis than secondary metastatic breast cancers even though they tend to metastasize early.en_US
dc.identifier.doi10.4328/ACAM.21541
dc.identifier.endpage370en_US
dc.identifier.issn2667-663X
dc.identifier.issue4en_US
dc.identifier.startpage365en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.21541
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16551
dc.identifier.volume14en_US
dc.identifier.wosWOS:000967636400018en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals Of Clinical And Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectDe Noven_US
dc.subjectMetastasis Survivalen_US
dc.titleOur clinical experiences in patients with de novo and secondary metastatic breast cancersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu